Ivan Bozin
Overview
Explore the profile of Ivan Bozin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pandey K, Giles K, Balashov K, Macdonell R, Windsheimer J, Martinez M, et al.
Neurol Ther
. 2024 Dec;
14(1):243-260.
PMID: 39673658
Introduction: Dimethyl fumarate (DMF) has demonstrated a favorable benefit-risk profile in patients with relapsing-remitting multiple sclerosis (RRMS) in clinical and real-world studies. The ESTEEM study (NCT02047097) was conducted to assess...
2.
Mao-Draayer Y, Bar-Or A, Balashov K, Foley J, Smoot K, Longbrake E, et al.
Adv Ther
. 2024 Nov;
42(1):395-412.
PMID: 39570545
Introduction: Real-world studies in the USA report that 41-56% of patients with multiple sclerosis (MS) are ≥ 50 years old, yet data on their response to disease-modifying therapies (DMTs) is...
3.
Jiang T, Shanmugasundaram M, Bozin I, Freedman M, Lewin J, Shen C, et al.
J Comp Eff Res
. 2024 Aug;
13(10):e230161.
PMID: 39158844
Diroximel fumarate (DRF), ozanimod (OZA) and interferon beta-1a (IFN) are disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus OZA and IFN....
4.
Bowen J, Stulc J, Hunter S, Chen H, Lewin J, Scaramozza M, et al.
Adv Ther
. 2024 Jun;
41(8):3396-3406.
PMID: 38878121
Introduction: Diroximel fumarate (DRF) and dimethyl fumarate (DMF) are orally administered fumarate disease-modifying therapies (DMTs) for multiple sclerosis (MS). The safety, tolerability, and exploratory efficacy of DRF were evaluated in...
5.
Spelman T, Eichau S, Alroughani R, Ozakbas S, Khoury S, Patti F, et al.
Mult Scler J Exp Transl Clin
. 2024 May;
10(2):20552173241247182.
PMID: 38800132
Background: The use of non-specific immunosuppressants (NSIS) to treat multiple sclerosis (MS) remains prevalent in certain geographies despite safety concerns, likely due to resource limitations. Objective: To use MSBase registry...
6.
Lager B, Liseno J, Bozin I, Sarah M England , Shankar S, Mendoza J, et al.
Neurol Ther
. 2023 Sep;
12(6):2199-2203.
PMID: 37707704
No abstract available.
7.
Tremblay M, Vukusic S, Shanmugasundaram M, Bozin I, Levin S, Gocke A, et al.
Mult Scler J Exp Transl Clin
. 2023 Sep;
9(3):20552173231191170.
PMID: 37692293
People with multiple sclerosis (pwMS) have an increased risk of infection. As disease-modifying therapies (DMTs) and other treatments may interact with the immune system, there may be concerns about vaccine...
8.
Williams M, Amezcua L, Chinea A, Cohan S, Okai A, Okuda D, et al.
Neurol Ther
. 2023 Jun;
12(5):1669-1682.
PMID: 37354276
Introduction: Multiple sclerosis (MS) clinical trials have included low numbers of patients from racial and ethnic minority populations; therefore, it is uncertain whether differences exist in response to disease-modifying therapies....
9.
Jiang T, Ziemssen T, Wray S, Shen C, Soderbarg K, Lewin J, et al.
CNS Drugs
. 2023 May;
37(5):441-452.
PMID: 37155132
Introduction: Diroximel fumarate (DRF), ponesimod (PON), and teriflunomide (TERI) are oral disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus PON or...
10.
Lager B, Liseno J, Bozin I, Sarah M England , Shankar S, Mendoza J, et al.
Neurol Ther
. 2022 Nov;
12(1):145-159.
PMID: 36334241
Introduction: Adherence to disease-modifying therapies is key for achieving optimal outcomes in multiple sclerosis (MS). Diroximel fumarate (DRF) is an oral fumarate approved for treatment of relapsing forms of MS....